Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03850574

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia — APTIVATE  

Relapsed or Refractory Acute Myeloid Leukemia Clinical Trial

Official title:
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Summary

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Description

This is a Phase 1/2, open-label, multi-center study to assess the efficacy, safety, tolerability, pharmacokinetics, including recommended phase 2 dose (RP2D) of tuspetinib (HM43239) monotherapy in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). This study will also evaluate the safety, tolerability, and PK parameters of tuspetinib (HM43239) in combination with venetoclax when administered in patients with R/R AML ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03850574
Study type Interventional
Source Aptose Biosciences Inc.
Contact Rafael Bejar, MD, PhD
Phone 858-401-6852
Email rbejar@aptose.com
Status Recruiting
Phase Phase 1/Phase 2
Start date March 11, 2019
Completion date August 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04478695 - Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT05038800 - A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) Phase 1
Completed NCT04176393 - A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation Phase 1
Active, not recruiting NCT04666649 - Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Phase 1
Recruiting NCT04842370 - Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML Phase 1
Active, not recruiting NCT02675452 - AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05522192 - Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT03755154 - Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT05726110 - Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia Phase 3
Recruiting NCT03765541 - Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia Phase 3
Recruiting NCT05787496 - A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms Phase 1
Terminated NCT02623582 - CD123 Redirected Autologous T Cells for AML Early Phase 1
Withdrawn NCT02215629 - Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia Phase 1